Navigation und Service

PARC - Metabolic Disruption (PARC MDC)

05/2022-04/2025

Funding programme / funding institution: Europäische Union (EU) - Belgien

Grant number: 101057014

Project homepage: -

Project description:

Over the past decade, progress in endocrine disrupting chemicals (EDC) research has demonstrated that one specific adverse effect of a number of EDC is their capability to induce a lasting disruption of endogenous metabolism. These substances, referred as "metabolism disrupting chemicals" (MDC) are largely suspected to contribute to the incidence of obesity and related metabolic disorders such as type II diabetes and non-alcoholic fatty liver disease, in association with genetic factors, nutrition and lifestyle. Nowadays, more than 50 million people in Europe suffer from metabolic disorders with the role of environmental stressors (either man-made or natural chemicals) being increasingly recognized.

According to WHO/IPSC (2002), specific criteria should be fulfilled for a substance to be considered as an EDC/MDC. Despite MDC are suspected to play a major role in the worldwide epidemics of metabolic disorders, there are currently no specific regulatory in vivo or in vitro tests allowing to identify their adverse effects. From a regulatory perspective, it is thus of paramount importance to validate methodologies allowing to identify and assess MDC-associated risks. This section will focus on the development of new approach methodologies (NAM) allowing to answer key regulatory needs.

Specific compounds under investigation will come from the PARC priority list (BPA alternatives), other EU projects such as the EURION Cluster, and agencies like ECHA or EFSA.

Project partners

• Leibniz-Institut für Arbeitsforschung an der TU Dortmund (IfADo) - Deutschland
• French National Institute for Agriculture, Food, and Environment (INRAE) - Frankreich
• Universität Utrecht (UU) - Niederlande
• Helmholtz-Zentrum für Umweltforschung GmbH (UFZ) Leipzig - Deutschland
• French National Institute of Health and Medical Research (Inserm) - Frankreich

Up